GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (LSE:AZN) » Definitions » Cyclically Adjusted PS Ratio

AstraZeneca (LSE:AZN) Cyclically Adjusted PS Ratio : 6.37 (As of May. 14, 2024)


View and export this data going back to 1993. Start your Free Trial

What is AstraZeneca Cyclically Adjusted PS Ratio?

As of today (2024-05-14), AstraZeneca's current share price is £123.18. AstraZeneca's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was £19.35. AstraZeneca's Cyclically Adjusted PS Ratio for today is 6.37.

The historical rank and industry rank for AstraZeneca's Cyclically Adjusted PS Ratio or its related term are showing as below:

LSE:AZN' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.42   Med: 3.87   Max: 6.78
Current: 6.37

During the past years, AstraZeneca's highest Cyclically Adjusted PS Ratio was 6.78. The lowest was 2.42. And the median was 3.87.

LSE:AZN's Cyclically Adjusted PS Ratio is ranked worse than
85.91% of 745 companies
in the Drug Manufacturers industry
Industry Median: 2.17 vs LSE:AZN: 6.37

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AstraZeneca's adjusted revenue per share data for the three months ended in Mar. 2024 was £6.396. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is £19.35 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


AstraZeneca Cyclically Adjusted PS Ratio Historical Data

The historical data trend for AstraZeneca's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Cyclically Adjusted PS Ratio Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.04 4.89 5.51 6.30 5.55

AstraZeneca Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.19 6.04 5.85 5.55 5.52

Competitive Comparison of AstraZeneca's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted PS Ratio falls into.



AstraZeneca Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

AstraZeneca's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=123.18/19.35
=6.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, AstraZeneca's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=6.396/130.0000*130.0000
=6.396

Current CPI (Mar. 2024) = 130.0000.

AstraZeneca Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 3.162 99.800 4.119
201409 3.210 100.000 4.173
201412 3.395 99.900 4.418
201503 3.203 99.600 4.181
201506 3.201 100.100 4.157
201509 3.064 100.200 3.975
201512 3.379 100.400 4.375
201603 3.393 100.400 4.393
201606 3.118 101.000 4.013
201609 3.426 101.500 4.388
201612 3.534 102.200 4.495
201703 3.458 102.700 4.377
201706 3.116 103.500 3.914
201709 3.689 104.300 4.598
201712 3.393 105.000 4.201
201803 2.926 105.100 3.619
201806 3.060 105.900 3.756
201809 3.224 106.600 3.932
201812 4.001 107.100 4.856
201903 3.287 107.000 3.994
201906 3.502 107.900 4.219
201909 3.945 108.400 4.731
201912 3.873 108.500 4.640
202003 3.910 108.600 4.680
202006 3.819 108.800 4.563
202009 3.871 109.200 4.608
202012 4.199 109.400 4.990
202103 4.001 109.700 4.741
202106 4.447 111.400 5.189
202109 4.801 112.400 5.553
202112 5.783 114.700 6.554
202203 5.538 116.500 6.180
202206 5.606 120.500 6.048
202209 6.220 122.300 6.612
202212 5.898 125.300 6.119
202303 5.746 126.800 5.891
202306 5.796 129.400 5.823
202309 5.952 130.100 5.947
202312 6.058 130.000 6.058
202403 6.396 130.000 6.396

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AstraZeneca  (LSE:AZN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


AstraZeneca Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca (LSE:AZN) Business Description

Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

AstraZeneca (LSE:AZN) Headlines

From GuruFocus